This study will use a randomized controlled design to test whether patients who use medical marijuana, compared to a waitlist control group, experience a change in health outcomes (relief of symptoms, or adverse health outcomes such as new-onset symptoms of cannabis use disorders, neurocognitive impairments) or brain-based changes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Mean Difference in Number of Cannabis Use Disorder Symptoms Averaged Over 2, 4, and 12 Weeks
Timeframe: 2 weeks, 4 weeks, and 12 weeks
Mean Difference in Depression Subscale Scores From the HADS Averaged Over 2, 4, and 12 Weeks
Timeframe: 2 weeks, 4 weeks, and 12 weeks
Mean Difference in Anxiety Subscale Scores From the HADS Averaged Over 2, 4, and 12 Weeks
Timeframe: 2 Weeks, 4 Weeks, and 12 Weeks
Mean Difference in Pain Severity Scores on the BPI Average Over 2, 4, and 12 Weeks
Timeframe: 2 weeks, 4 weeks, and 12 weeks
Mean Difference in Sleep Scores on the AIS Averaged Over 2, 4, and 12 Weeks
Timeframe: 2 weeks, 4 weeks, and 12 weeks